Mesoblast Bolsters Platform With CAR License

Mesoblast announced that it has secured an exclusive worldwide license to a patented CAR technology designed to enhance its MSC cell products. The deal broadens its technology base and could support the development of new, higher-value therapies, seen as positive for medium-term growth potential. The stock also benefits from a favorable market backdrop, with analysts remaining bullish and price targets still well above the current share price. Meanwhile, FDA clearance for a pivotal trial in DMD and progress in several Phase III programs are improving visibility for the group, even though it remains a high-risk biotech name.